Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a
single oral drug. The purpose of this study is to assess the safety and effectiveness of two
doses of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when
added to glimepiride in people with type 2 diabetes not at target blood glucose levels on a
sulfonylurea alone.